We came across a bullish thesis on Natera on Base by Base’s Substack by Edward Larkin. As of 9ᵗʰ July, Natera’s share was trading at $158.48. NTRA’s forward P/E was -130.98 according to Yahoo Finance.
An oncologist discussing an anti-PD1 therapy option with a patient.
The article discusses the revolutionary potential of circulating tumor DNA (ctDNA) in oncology, particularly in the context of cancer treatment and clinical trials. ctDNA tests are becoming more sensitive and...
